"Methotrexate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
| Descriptor ID |
D008727
|
| MeSH Number(s) |
D03.633.100.733.631.192.500
|
| Concept/Terms |
Methotrexate Sodium- Methotrexate Sodium
- Sodium, Methotrexate
- Methotrexate, Sodium Salt
- Methotrexate, Disodium Salt
|
Below are MeSH descriptors whose meaning is more general than "Methotrexate".
Below are MeSH descriptors whose meaning is more specific than "Methotrexate".
This graph shows the total number of publications written about "Methotrexate" by people in this website by year, and whether "Methotrexate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 3 | 4 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 3 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 3 | 2 | 5 |
| 2002 | 2 | 2 | 4 |
| 2003 | 3 | 4 | 7 |
| 2004 | 1 | 3 | 4 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 3 | 4 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 4 | 1 | 5 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 1 | 5 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 4 | 6 |
| 2020 | 2 | 4 | 6 |
| 2021 | 0 | 4 | 4 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 0 | 2 |
| 2026 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methotrexate" by people in Profiles.
-
Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12; 147(11):1168-1177.
-
Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro Oncol. 2026 Feb 01; 28(2):371-382.
-
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Adv. 2024 08 27; 8(16):4294-4310.
-
Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients. J Am Acad Dermatol. 2024 06; 90(6):1271-1275.
-
Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines. Pediatr Dermatol. 2023 Sep-Oct; 40(5):789-808.
-
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 07; 82(7):920-926.
-
Low-dose Methotrexate Therapy Does Not Affect Semen Parameters and Sperm DNA. Inflamm Bowel Dis. 2022 07 01; 28(7):1012-1018.
-
SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 05 10; 40(14):1574-1582.
-
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 01 20; 139(3):413-423.
-
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep. 2022 02; 17(1):1-14.